"The FDA has prevented any trial from being started from about 2020."
Well that's clearly misleading given that the FDA recommended that Mesoblaat conduct at least one randomized well trial in adults or children for aGVHD. It was SI that claimed they had been told they couldn't do another trial until the potency assay was validated. I strongly suspect that applied only to single arm trials
Ann: Mesoblast Corporate Presentation, page-28
-
- There are more pages in this discussion • 35 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.38 |
Change
-0.080(5.50%) |
Mkt cap ! $1.569B | |||
| Open | High | Low | Value | Volume |
| $1.43 | $1.43 | $1.37 | $5.321M | 3.829M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 12214 | $1.38 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.38 | 37660 | 5 |
View Market Depth
| Last trade - 16.10pm 16/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |